Research Article
Subklinik hipotroidi hasta serumlarında homosistein ve irisin seviyelerinin tanısal öneminin belirlenmesi
Abstract
Amaç: Bu çalışmanın amacı, subklinik hipotiroidi (SH) hastalarının serumlarında irisin ve homosistein (Hcy) düzeylerinin tanısal önemini belirlemektir.
Yöntemler: Çalışmada 80 kişi değerlendirildi. Hasta grubuna, SH tanısı konmuş 40 hasta ve kontrol grubuna 40 sağlıklı birey dahil edildi. Kan örnekleri toplandı ve enzim bağlı immünosorbent testi (ELISA) kullanılarak serum irisin ve Hcy düzeyleri belirlendi. Tiroid uyarıcı hormon (TSH), serbest triiyodotironin (fT3), serbest tiroksin (fT4) düzeyleri Cobas e 601 otoanalizörü kullanılarak kemilüminesans yöntemiyle ölçüldü.
Bulgular: SH hastalarında Irisin, Hcy, TSH düzeyleri kontrol grubuna göre anlamlı olarak yüksek bulundu (sırasıyla p = 0.0001, p = 0.0001, p = 0.0001). Ayrıca, İrisin ve Hcy seviyeleri TSH seviyeleri kadar spesifik ve sensitifti. SH için en iyi kesme noktaları, İrisin için > 14.43 ng / mL, Hcy için > 13.53 nmol / ml ve TSH için > 4.11 uUI / mL idi.
Sonuç: Irisin, Hcy SH için tanısal bir biyobelirteç olarak kullanılabilir.
Keywords
References
- 1. Cojić M, Cvejanov-Kezunović L. Subclinical Hypothyroidism – Whether and When To Start Treatment. Maced J Med Sci. 2017; 15; 5: 1042-6. 2. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98: E769-78. 3. Ateş İ, Altay M, Topçuoğlu C, Yılmaz FM. Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Arch Endocrinol Metab. 2016; 60: 95-100. 4. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol. 2016; 67: 476-80. 5. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharmacol Sci 2014; 125: 125e131. 6. Hofmann T, Elbelt U, Stengel A. Irisin as a muscle-derived hormone stimulating thermogenesisea critical update. Peptides 2014; 54: 89e100. 7. Moreno M, Moreno-Navarrete JM, Serrano M, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS One. 2015; 10: e0124100. 8. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014; 63: 1265-71. 9. Kuloglu T, Aydin S, Eren MN, et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides. 2014; 55C: 85–91. 10. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis. 2001; 155: 195–200. 11. Bamashmoos SA, Al-Nuzaily MA, Al-Meeri AM, Ali FH. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. Springerplus. 2013; 30: 423. Altay D.U., Ozdemır O., Noyan T., Yuksel S., Ayhan B.S. 756 12. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 2009; 60: 39–54. 13. Selmer C, Olesen JB, Hansen ML,et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99: 2372–82. 14. Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97: 852–61. 15. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126: 1040–9. 16. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid Dysfunction and Heart Failure: Mechanisms and Associations. Curr Heart Fail Rep. 2017; 14: 48–58. 17. McAninch EA, Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. Ann N Y Acad Sci. 2014; 1311: 77–87. 18. Zarković M. The deficit of thyroid hormones - effect on cardiovascular and cognitive functions. (srb. Deficit tiroidnih hormona – uticaj na kardiovaskularne i kognitivne funkcije.) Medical Gazette Special hospital for thyroid gland diseases and metabolic diseases Zlatibor (srb. Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor). 2007; 12: 47-53. 19. Klein I, Ojamaa K. Thyroid hormone and cardiovascular System. N Engl J Med. 2001; 344: 501-9. 20. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010; 52: 151–6. 21. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003; 88: 2438–44. 22. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I.Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp 2012; 61: 1725–38. 23. Samy DM, Ismail CA, Nassra RA. Circulating irisin concentrations in rat models of thyroid dysfunction – effect of exercise. Metabolism 2015; 64: 804–13. 24. Ruchala M, Zybek A, Szczepanek-Parulska E. Serum irisin levels and thyroid function – Newly discovered association. Peptides. 2014; 60: 51-5. 25. Yalcin MM, Akturk M, Tohma Y, et al. Irisin and myostatin levels in patients with Graves' disease. Arch Med Res 2016; 47: 471-5. 26. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 2016; 67: 476-80 27. Ellefsen S, Vikmoen O, Slettaløkken G, et al. Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women. Eur J Appl Physiol 2014: 114; 1875–88. 28. Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – correlation with body mass index. Peptides 2013; 39: 125–30.
Year 2019,
Volume: 46 Issue: 4, 751 - 756, 15.12.2019
Abstract
References
- 1. Cojić M, Cvejanov-Kezunović L. Subclinical Hypothyroidism – Whether and When To Start Treatment. Maced J Med Sci. 2017; 15; 5: 1042-6. 2. Moreno-Navarrete JM, Ortega F, Serrano M, et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance. J Clin Endocrinol Metab. 2013; 98: E769-78. 3. Ateş İ, Altay M, Topçuoğlu C, Yılmaz FM. Circulating levels of irisin is elevated in hypothyroidism, a case-control study. Arch Endocrinol Metab. 2016; 60: 95-100. 4. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol. 2016; 67: 476-80. 5. Iizuka K, Machida T, Hirafuji M. Skeletal muscle is an endocrine organ. J Pharmacol Sci 2014; 125: 125e131. 6. Hofmann T, Elbelt U, Stengel A. Irisin as a muscle-derived hormone stimulating thermogenesisea critical update. Peptides 2014; 54: 89e100. 7. Moreno M, Moreno-Navarrete JM, Serrano M, et al. Circulating irisin levels are positively associated with metabolic risk factors in sedentary subjects. PLoS One. 2015; 10: e0124100. 8. Panagiotou G, Mu L, Na B, Mukamal KJ, Mantzoros CS. Circulating irisin, omentin-1, and lipoprotein subparticles in adults at higher cardiovascular risk. Metabolism. 2014; 63: 1265-71. 9. Kuloglu T, Aydin S, Eren MN, et al. Irisin: a potentially candidate marker for myocardial infarction. Peptides. 2014; 55C: 85–91. 10. Morris MS, Bostom AG, Jacques PF, Selhub J, Rosenberg IH. Hyperhomocysteinemia and hypercholesterolemia associated with hypothyroidism in the third US National Health and Nutrition Examination Survey. Atherosclerosis. 2001; 155: 195–200. 11. Bamashmoos SA, Al-Nuzaily MA, Al-Meeri AM, Ali FH. Relationship between total homocysteine, total cholesterol and creatinine levels in overt hypothyroid patients. Springerplus. 2013; 30: 423. Altay D.U., Ozdemır O., Noyan T., Yuksel S., Ayhan B.S. 756 12. Maron BA, Loscalzo J. The treatment of hyperhomocysteinemia. Annu Rev Med 2009; 60: 39–54. 13. Selmer C, Olesen JB, Hansen ML,et al. Subclinical and overt thyroid dysfunction and risk of all-cause mortality and cardiovascular events: a large population study. J Clin Endocrinol Metab 2014; 99: 2372–82. 14. Nanchen D, Gussekloo J, Westendorp RG, et al. Subclinical thyroid dysfunction and the risk of heart failure in older persons at high cardiovascular risk. J Clin Endocrinol Metab 2012; 97: 852–61. 15. Gencer B, Collet TH, Virgini V, et al. Subclinical thyroid dysfunction and the risk of heart failure events: an individual participant data analysis from 6 prospective cohorts. Circulation 2012; 126: 1040–9. 16. Vargas-Uricoechea H, Bonelo-Perdomo A. Thyroid Dysfunction and Heart Failure: Mechanisms and Associations. Curr Heart Fail Rep. 2017; 14: 48–58. 17. McAninch EA, Bianco AC. Thyroid hormone signaling in energy homeostasis and energy metabolism. Ann N Y Acad Sci. 2014; 1311: 77–87. 18. Zarković M. The deficit of thyroid hormones - effect on cardiovascular and cognitive functions. (srb. Deficit tiroidnih hormona – uticaj na kardiovaskularne i kognitivne funkcije.) Medical Gazette Special hospital for thyroid gland diseases and metabolic diseases Zlatibor (srb. Medicinski glasnik Specijalna bolnica za bolesti štitaste žlezde i bolesti metabolizma Zlatibor). 2007; 12: 47-53. 19. Klein I, Ojamaa K. Thyroid hormone and cardiovascular System. N Engl J Med. 2001; 344: 501-9. 20. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010; 52: 151–6. 21. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003; 88: 2438–44. 22. Huh JY, Panagiotou G, Mougios V, et al. FNDC5 and irisin in humans: I.Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise. Metab Clin Exp 2012; 61: 1725–38. 23. Samy DM, Ismail CA, Nassra RA. Circulating irisin concentrations in rat models of thyroid dysfunction – effect of exercise. Metabolism 2015; 64: 804–13. 24. Ruchala M, Zybek A, Szczepanek-Parulska E. Serum irisin levels and thyroid function – Newly discovered association. Peptides. 2014; 60: 51-5. 25. Yalcin MM, Akturk M, Tohma Y, et al. Irisin and myostatin levels in patients with Graves' disease. Arch Med Res 2016; 47: 471-5. 26. Zybek-Kocik A, Sawicka-Gutaj N, Wrotkowska E, Sowiński J, Ruchała M. Time-dependent irisin concentration changes in patients affected by overt hypothyroidism. Endokrynol Pol 2016; 67: 476-80 27. Ellefsen S, Vikmoen O, Slettaløkken G, et al. Irisin and FNDC5: effects of 12-week strength training, and relations to muscle phenotype and body mass composition in untrained women. Eur J Appl Physiol 2014: 114; 1875–88. 28. Stengel A, Hofmann T, Goebel-Stengel M, et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity – correlation with body mass index. Peptides 2013; 39: 125–30.
There are 1 citations in total.
Details
| Primary Language | Turkish |
|---|---|
| Subjects | Health Care Administration |
| Journal Section | Research Article |
| Authors | |
| Publication Date | December 15, 2019 |
| Submission Date | June 27, 2019 |
| Published in Issue | Year 2019 Volume: 46 Issue: 4 |